Keenova Therapeutics plc

Item 8.01. Other Events. On July 31, 2026, Keenova Therapeutics plc (the “Company”) closed the previously disclosed sale of its Percocet and Endocet businesses (the “Business”) to Par Health, Inc (“Par Health”). Consideration for the transaction is expected to total approximately $250.0 million, consisting of an upfront purchase price of $25.0 million, subject to customary adjustments for cash, debt and working capital, and quarterly earnout payments payable in cash, related to the gross profit of the Business over a period of five years following the closing of the transaction. Following closing of the transaction and completion of related transition services, the Company will no longer market, manufacture or distribute opioid products. Information Regarding Forward-Looking Statements This Current Report on Form 8-K includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “expect,” “intend,” “will,” “may,” “plan,” “believe” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements in this Current Report include statements regarding the expected total consideration. These statements are based on various assumptions, whether or not identified in this Current Report on Form 8-K, and on current expectations and are not predictions of actual performance. Therefore, you should not rely on any of these forward-looking statements. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including the performance of the Business and its ability to generate gross profits following the closing of the transaction and other risks and uncertainties affecting the Company, including those described under the caption “Risk Factors” and elsewhere in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on April 15, 2026, and other filings and furnishing with the SEC. These filings, when available, are available on the investor relations section of the Company’s website at https://investor.keenova.com/ or on the SEC’s website at https://www.sec.gov. The forward-looking statements included in this current report are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.